Analyst Research

Report Title Price
Provider: New Constructs, LLC
Provider: S&P Capital IQ Quantitative Report
Provider: Thomson Reuters Stock Report
Provider: MacroRisk Analytics/EconomicInvestor

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Isis Pharmaceuticals Inc Revises FY 2012 Earnings Guidance-Conference Call

Tuesday, 6 Nov 2012 04:30pm EST 

Isis Pharmaceuticals Inc announced that because of the timing change for the second KYNAMRO milestone and the accounting change for GSK transactions, it is adjusting net operating loss (NOL) guidance to the mid $70 million range for fiscal 2012. 

Company Quote

1.28 +4.47%
22 Jul 2014